Literature DB >> 11014928

Disorders of the epithelial Na(+) channel in Liddle's syndrome and autosomal recessive pseudohypoaldosteronism type 1.

Y S Oh1, D G Warnock.   

Abstract

The epithelial Na(+) channel (ENaC) is the key step in many Na(+)-absorptive epithelia, such as kidney and distal colon, that controls the overall rate of transepithelial Na(+) transport. ENaC is composed of three homologous subunits, alpha, beta, and gamma. The alpha subunit is the key subunit for the formation of a functional ion channel, while the beta and gamma subunits can greatly potentiate the level of expressed Na(+) currents. ENaCs belong to the recently identified DEG/ENaC supergene family, sharing the same basic structure with cytoplasmic amino and carboxy termini, two transmembrane regions, and a large extracellular loop. The human ENaC genes have been cloned, and using genetic linkage analysis the involvement of ENaC gene mutations in two distinct human diseases, Liddle's syndrome and autosomal recessive pseudohypoaldosteronism type 1 (PHA-1), has been demonstrated. In Liddle's syndrome, gain-of-function mutations in the beta or gamma ENaC subunits have been found; all identified mutations so far reside in the carboxy terminus of the protein, either deleting or modifying the functionally important PY motif. In PHA-1, loss-of-function mutations in the alpha, beta, or gamma subunits have been found; these mutations either truncate a significant portion of the structure or modify an amino acid that plays an important role in channel function. In this review, our current understanding about ENaC and the pathophysiology of Liddle's syndrome and PHA-1 caused by ENaC mutations will be discussed. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014928     DOI: 10.1159/000020685

Source DB:  PubMed          Journal:  Exp Nephrol        ISSN: 1018-7782


  7 in total

Review 1.  Regulation of renal sodium handling through the interaction between serine proteases and serine protease inhibitors.

Authors:  Kenichiro Kitamura; Kimio Tomita
Journal:  Clin Exp Nephrol       Date:  2010-06-11       Impact factor: 2.801

Review 2.  Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension.

Authors:  Kenichiro Kitamura; Kimio Tomita
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

3.  The serine protease plasmin plays detrimental roles in epithelial sodium channel activation and podocyte injury in Dahl salt-sensitive rats.

Authors:  Qinyuan Deng; Yutaka Kakizoe; Yasunobu Iwata; Terumasa Nakagawa; Yoshikazu Miyasato; Miyuki Nakagawa; Kayo Nishiguchi; Yu Nagayoshi; Masataka Adachi; Yuki Narita; Yuichiro Izumi; Takashige Kuwabara; Yuko Tsuda; Masashi Mukoyama
Journal:  Hypertens Res       Date:  2022-10-15       Impact factor: 5.528

Review 4.  Assessment of the CFTR and ENaC association.

Authors:  Bakhrom K Berdiev; Yawar J Qadri; Dale J Benos
Journal:  Mol Biosyst       Date:  2008-12-03

5.  Abnormal urinary excretion of NKCC2 and AQP2 in response to hypertonic saline in chronic kidney disease: an intervention study in patients with chronic kidney disease and healthy controls.

Authors:  Janni M Jensen; Frank H Mose; Anna-Ewa O Kulik; Jesper N Bech; Robert A Fenton; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2014-06-26       Impact factor: 2.388

6.  High Salt Diet Affects Renal Sodium Excretion and ERRα Expression.

Authors:  Dan Wang; Yang Wang; Fu-Qiang Liu; Zu-Yi Yuan; Jian-Jun Mu
Journal:  Int J Mol Sci       Date:  2016-04-01       Impact factor: 5.923

7.  The molecular chaperone GRP170 protects against ER stress and acute kidney injury in mice.

Authors:  Aidan W Porter; Diep N Nguyen; Dennis R Clayton; Wily G Ruiz; Stephanie M Mutchler; Evan C Ray; Allison L Marciszyn; Lubika J Nkashama; Arohan R Subramanya; Sebastien Gingras; Thomas R Kleyman; Gerard Apodaca; Linda M Hendershot; Jeffrey L Brodsky; Teresa M Buck
Journal:  JCI Insight       Date:  2022-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.